

VCORE PEPTIDES

vcorepeptides.com


In Partnership with Vialora Ventures, LLC

Certificate of Analysis — Compiled Catalog

All Batches · June 3 – March 4, 2026 · Most Recent First

Total Samples Tested	Testing Laboratory	Methodology
37	Freedom Diagnostics	HPLC-UV + LC-MS/MS
Batches	Average Purity	Pass Rate
6	99.594%	100% (all ≥99.0%)
Purity Range	Highest Result	Lowest Result
99.002% – 99.970%	99.97% (Selank 10mg)	99.00% (BPC-157 / TB-500 Blend)


Purity by Sample — All Batches



Purity Scale Note: Chart y-axis starts at 98.5 to emphasize variation within the 99–100% range. All samples confirmed ≥99.0% purity. Three June 3 samples submitted as oral tablets.

VCORE PEPTIDES

Batch Date: June 3, 2026 · Reported: June 7 · 5 samples · Batch Avg 99.694%



BPC-157 / TB-500 Blend

COA: 2606030687

99.270%

PASS

Identity	BPC-157 / Thymosin Beta-4	Lot / Cap Color	Red Cap
Net Content	BPC-157 11.65mg · TB4 11.33mg	Labeled Amount	10mg / 10mg (~20mg)
Appearance	White Lyophilized Powder	Method	HPLC-UV + LC-MS/MS
Date Tested	June 3, 2026	Reported	June 7, 2026
Purity Testing	Purity quantified via HPLC-UV. Sample form: Lyophilized Vial . Tested as reconstitutable lyophilized powder.		

Dual-peptide blend; both components confirmed.

Retatrutide 10mg

COA: 2606030688

99.940%

PASS

Identity	GLP RT (Retatrutide)	Lot / Cap Color	Yellow Cap
Net Content	12.01 mg	Labeled Amount	10 mg
Appearance	White Lyophilized Powder	Method	HPLC-UV + LC-MS/MS
Date Tested	June 3, 2026	Reported	June 7, 2026
Purity Testing	Purity quantified via HPLC-UV. Sample form: Lyophilized Vial . Tested as reconstitutable lyophilized powder.		

Net 20.1% over label. Highest-purity Retatrutide lot to date.

Tesofensine (Oral)

COA: 2606030689

99.850%

PASS

Identity	Tesofensine	Lot / Cap Color	N/A
Net Content	Not requested	Labeled Amount	—
Appearance	White Tablets	Method	HPLC-UV + LC-MS/MS
Date Tested	June 3, 2026	Reported	June 7, 2026
Purity Testing	Purity quantified via HPLC-UV. Sample form: Oral Tablet . Tested as oral tablet.		

Oral tablet format. Net content not requested.


VCORE PEPTIDES

BPC-157 (Oral)		COA: 2606030690	99.830%	PASS
Identity	BPC-157	Lot / Cap Color	N/A	
Net Content	Not requested	Labeled Amount	—	
Appearance	White Tablets	Method	HPLC-UV + LC-MS/MS	
Date Tested	June 3, 2026	Reported	June 7, 2026	
Purity Testing	Purity quantified via HPLC-UV. Sample form: Oral Tablet. Tested as oral tablet.			
Oral tablet format. Net content not requested.				

SLU-PP-332 (Oral)		COA: 2606030691	99.580%	PASS
Identity	SLU-PP-332	Lot / Cap Color	N/A	
Net Content	Not requested	Labeled Amount	—	
Appearance	White Tablets	Method	HPLC-UV + LC-MS/MS	
Date Tested	June 3, 2026	Reported	June 7, 2026	
Purity Testing	Purity quantified via HPLC-UV. Sample form: Oral Tablet. Tested as oral tablet.			
Oral tablet format. Net content not requested.				

VCORE PEPTIDES

Batch Date: May 7, 2026 · Reported: May 9 · 6 samples · Batch Avg 99.415%



Selank 10mg

COA: 2605070060

99.970%

PASS

Identity	Selank	Lot / Cap Color	Grey Cap
Net Content	13.24 mg	Labeled Amount	10 mg
Appearance	White Lyophilized Powder	Method	HPLC-UV + LC-MS/MS
Date Tested	May 7, 2026	Reported	May 9, 2026
Purity Testing	Purity quantified via HPLC-UV. Sample form: Lyophilized Vial . Tested as reconstitutable lyophilized powder.		

Highest purity in full dataset. Net 32.4% over label.

Epithalon 10mg

COA: 2605070061

99.170%

PASS

Identity	Epithalon (Epithalon)	Lot / Cap Color	White Cap
Net Content	12.62 mg	Labeled Amount	10 mg
Appearance	White Lyophilized Powder	Method	HPLC-UV + LC-MS/MS
Date Tested	May 7, 2026	Reported	May 9, 2026
Purity Testing	Purity quantified via HPLC-UV. Sample form: Lyophilized Vial . Tested as reconstitutable lyophilized powder.		

Net 26.2% over label. Glycine trace in chromatogram.

KPV 10mg

COA: 2605070062

99.490%

PASS

Identity	KPV	Lot / Cap Color	White Cap
Net Content	12.48 mg	Labeled Amount	10 mg
Appearance	White Lyophilized Powder	Method	HPLC-UV + LC-MS/MS
Date Tested	May 7, 2026	Reported	May 9, 2026
Purity Testing	Purity quantified via HPLC-UV. Sample form: Lyophilized Vial . Tested as reconstitutable lyophilized powder.		

Net 24.8% over label. Glycine trace in chromatogram.

VCORE PEPTIDES


Sermorelin 10mg		COA: 2605070063	99.100%	PASS
Identity	Sermorelin	Lot / Cap Color	White Cap	
Net Content	10.56 mg	Labeled Amount	10 mg	
Appearance	White Lyophilized Powder	Method	HPLC-UV + LC-MS/MS	
Date Tested	May 7, 2026	Reported	May 9, 2026	
Purity Testing	Purity quantified via HPLC-UV. Sample form: Lyophilized Vial . Tested as reconstitutable lyophilized powder.			
Net content on label. Glycine trace visible.				

IGF-1 LR3		COA: 2605070065	99.700%	PASS
Identity	IGF-LR3	Lot / Cap Color	Blue Cap	
Net Content	0.88 mg	Labeled Amount	~1 mg	
Appearance	White Lyophilized Powder	Method	HPLC-UV + LC-MS/MS	
Date Tested	May 7, 2026	Reported	May 9, 2026	
Purity Testing	Purity quantified via HPLC-UV. Sample form: Lyophilized Vial . Tested as reconstitutable lyophilized powder.			
Net slightly under; within tolerance for high-value peptide.				

GHK-Cu 100mg		COA: 2605070066	99.060%	PASS
Identity	GHK-Cu	Lot / Cap Color	Dark Blue Cap	
Net Content	102.93 mg	Labeled Amount	100 mg	
Appearance	Blue Lyophilized Powder	Method	HPLC-UV + LC-MS/MS	
Date Tested	May 7, 2026	Reported	May 9, 2026	
Purity Testing	Purity quantified via HPLC-UV. Sample form: Lyophilized Vial . Tested as reconstitutable lyophilized powder.			
Net 2.9% over label. Distinctive blue powder.				

VCORE PEPTIDES

Batch Date: April 3, 2026 · Reported: April 5 · 7 samples · Batch Avg 99.726%



Retatrutide 20mg

COA: 2604030139

99.924%

PASS

Identity	GLP RT (Retatrutide)	Lot / Cap Color	White Cap
Net Content	24.55 mg	Labeled Amount	20 mg
Appearance	White Lyophilized Powder	Method	HPLC-UV + LC-MS/MS
Date Tested	April 3, 2026	Reported	April 5, 2026
Purity Testing	Purity quantified via HPLC-UV. Sample form: Lyophilized Vial . Tested as reconstitutable lyophilized powder.		

Highest purity across all Retatrutide lots.

Retatrutide 10mg

COA: 2604030141

99.889%

PASS

Identity	GLP RT (Retatrutide)	Lot / Cap Color	Clear Cap
Net Content	12.81 mg	Labeled Amount	10 mg
Appearance	White Lyophilized Powder	Method	HPLC-UV + LC-MS/MS
Date Tested	April 3, 2026	Reported	April 5, 2026
Purity Testing	Purity quantified via HPLC-UV. Sample form: Lyophilized Vial . Tested as reconstitutable lyophilized powder.		

Fourth Retatrutide lot; all lots >99.7%.

Epithalon 50mg

COA: 2604030142

99.484%

PASS

Identity	Epitalon (Epithalon)	Lot / Cap Color	Purple Cap
Net Content	46.71 mg	Labeled Amount	50 mg
Appearance	White Lyophilized Powder	Method	HPLC-UV + LC-MS/MS
Date Tested	April 3, 2026	Reported	April 5, 2026
Purity Testing	Purity quantified via HPLC-UV. Sample form: Lyophilized Vial . Tested as reconstitutable lyophilized powder.		

Net content 6.6% under label.

VCORE PEPTIDES

PT-141 10mg		COA: 2604030143	99.821%	PASS
Identity	PT-141 (Bremelanotide)	Lot / Cap Color	Pink Cap	
Net Content	9.71 mg	Labeled Amount	10 mg	
Appearance	White Lyophilized Powder	Method	HPLC-UV + LC-MS/MS	
Date Tested	April 3, 2026	Reported	April 5, 2026	
Purity Testing	Purity quantified via HPLC-UV. Sample form: Lyophilized Vial . Tested as reconstitutable lyophilized powder.			
Second PT-141 lot; consistent across batches.				


SS-31 10mg		COA: 2604030144	99.759%	PASS
Identity	SS-31 (Elamipretide)	Lot / Cap Color	Black Cap	
Net Content	9.55 mg	Labeled Amount	10 mg	
Appearance	White Lyophilized Powder	Method	HPLC-UV + LC-MS/MS	
Date Tested	April 3, 2026	Reported	April 5, 2026	
Purity Testing	Purity quantified via HPLC-UV. Sample form: Lyophilized Vial . Tested as reconstitutable lyophilized powder.			
Mitochondria-targeted antioxidant peptide.				

Glutathione 1500mg		COA: 2604030145	99.541%	PASS
Identity	Glutathione	Lot / Cap Color	Purple Cap	
Net Content	1481.26 mg	Labeled Amount	1500 mg	
Appearance	White Lyophilized Powder	Method	HPLC-UV + LC-MS/MS	
Date Tested	April 3, 2026	Reported	April 5, 2026	
Purity Testing	Purity quantified via HPLC-UV. Sample form: Lyophilized Vial . Tested as reconstitutable lyophilized powder.			
Net content 1.2% under label; within tolerance.				

Unknown / Unlabeled		COA: 2604030146	99.667%	PASS
Identity	Melanotan-II (by LC-MS/MS)	Lot / Cap Color	White Cap	
Net Content	9.61 mg	Labeled Amount	Unlabeled	
Appearance	White Lyophilized Powder	Method	HPLC-UV + LC-MS/MS	
Date Tested	April 3, 2026	Reported	April 5, 2026	
Purity Testing	Purity quantified via HPLC-UV. Sample form: Lyophilized Vial . Tested as reconstitutable lyophilized powder.			
Submitted unlabeled; identified as Melanotan-II by MS.				

VCORE PEPTIDES

Batch Date: March 24, 2026 · Reported: March 25 · 6 samples · Batch Avg 99.443%



Retatrutide 10mg

COA: 2603240023

99.791%

PASS

Identity	GLP RT (Retatrutide)	Lot / Cap Color	Clear Cap / Gold Crimp
Net Content	12.21 mg	Labeled Amount	10 mg
Appearance	White Lyophilized Powder	Method	HPLC-UV + LC-MS/MS
Date Tested	March 24, 2026	Reported	March 25, 2026
Purity Testing	Purity quantified via HPLC-UV. Sample form: Lyophilized Vial . Tested as reconstitutable lyophilized powder.		

Second lot; consistent purity across lots.

Tirzepatide 50mg

COA: 2603240024

99.569%

PASS

Identity	GLP TZ (Tirzepatide)	Lot / Cap Color	—
Net Content	58.01 mg	Labeled Amount	50 mg
Appearance	White Lyophilized Powder	Method	HPLC-UV + LC-MS/MS
Date Tested	March 24, 2026	Reported	March 25, 2026
Purity Testing	Purity quantified via HPLC-UV. Sample form: Lyophilized Vial . Tested as reconstitutable lyophilized powder.		

Net content 16% over label.

BPC-157 / TB-500 Blend

COA: 2603240025

99.002%

PASS

Identity	BPC-157 / Thymosin Beta-4	Lot / Cap Color	Clear Red Cap
Net Content	BPC-157 11.88mg · TB4 10.94mg	Labeled Amount	~22 mg
Appearance	White Lyophilized Powder	Method	HPLC-UV + LC-MS/MS
Date Tested	March 24, 2026	Reported	March 25, 2026
Purity Testing	Purity quantified via HPLC-UV. Sample form: Lyophilized Vial . Tested as reconstitutable lyophilized powder.		

Dual-peptide blend.

VCORE PEPTIDES


AOD-9604 10mg		COA: 2603240026	99.749%	PASS
Identity	AOD-9604	Lot / Cap Color	Red Cap	
Net Content	13.62 mg	Labeled Amount	10 mg	
Appearance	White Lyophilized Powder	Method	HPLC-UV + LC-MS/MS	
Date Tested	March 24, 2026	Reported	March 25, 2026	
Purity Testing	Purity quantified via HPLC-UV. Sample form: Lyophilized Vial . Tested as reconstitutable lyophilized powder.			
Net content 36.2% over label.				

Glow Blend 70mg		COA: 2603240027	99.521%	PASS
Identity	GHK-Cu / BPC-157 / Thymosin Beta-4	Lot / Cap Color	—	
Net Content	GHK-Cu 48.38mg · BPC-157 10.31mg · TB4 ~5mg	Labeled Amount	70 mg	
Appearance	White Lyophilized Powder	Method	HPLC-UV + LC-MS/MS	
Date Tested	March 24, 2026	Reported	March 25, 2026	
Purity Testing	Purity quantified via HPLC-UV. Sample form: Lyophilized Vial . Tested as reconstitutable lyophilized powder.			
Second lot; consistent formulation.				

5-Amino 1MQ		COA: 2603240028	99.029%	PASS
Identity	5-Amino 1MQ	Lot / Cap Color	Orange	
Net Content	6.41 mg	Labeled Amount	~6 mg	
Appearance	Orange Lyophilized Powder	Method	HPLC-UV + LC-MS/MS	
Date Tested	March 24, 2026	Reported	March 25, 2026	
Purity Testing	Purity quantified via HPLC-UV. Sample form: Lyophilized Vial . Tested as reconstitutable lyophilized powder.			
Distinctive orange powder.				

VCORE PEPTIDES

Batch Date: March 11, 2026 · Reported: March 12 · 8 samples · Batch Avg 99.580%



PT-141 10mg

COA: 2603110102

99.959%

PASS

Identity	PT-141 (Bremelanotide)	Lot / Cap Color	White Cap
Net Content	9.93 mg	Labeled Amount	10 mg
Appearance	White Lyophilized Powder	Method	HPLC-UV + LC-MS/MS
Date Tested	March 11, 2026	Reported	March 12, 2026
Purity Testing	Purity quantified via HPLC-UV. Sample form: Lyophilized Vial . Tested as reconstitutable lyophilized powder.		

Highest single-peptide purity across all batches.

Tirzepatide

COA: 2603110103

99.891%

PASS

Identity	GLP TZ (Tirzepatide)	Lot / Cap Color	White Cap
Net Content	Not requested	Labeled Amount	—
Appearance	White Lyophilized Powder	Method	HPLC-UV + LC-MS/MS
Date Tested	March 11, 2026	Reported	March 12, 2026
Purity Testing	Purity quantified via HPLC-UV. Sample form: Lyophilized Vial . Tested as reconstitutable lyophilized powder.		

Net content not requested by client.

TB-500 5mg

COA: 2603110104

99.498%

PASS

Identity	Thymosin Beta-4	Lot / Cap Color	White Cap
Net Content	5.77 mg	Labeled Amount	5 mg
Appearance	White Lyophilized Powder	Method	HPLC-UV + LC-MS/MS
Date Tested	March 11, 2026	Reported	March 12, 2026
Purity Testing	Purity quantified via HPLC-UV. Sample form: Lyophilized Vial . Tested as reconstitutable lyophilized powder.		

Net content 15.4% over label.

VCORE PEPTIDES

NAD+ 500mg		COA: 2603110105	99.822%	PASS
Identity	NAD+	Lot / Cap Color	White Cap	
Net Content	459.27 mg	Labeled Amount	500 mg	
Appearance	White Lyophilized Powder	Method	HPLC-UV + LC-MS/MS	
Date Tested	March 11, 2026	Reported	March 12, 2026	
Purity Testing	Purity quantified via HPLC-UV. Sample form: Lyophilized Vial . Tested as reconstitutable lyophilized powder.			
Net content 8.1% under label; within tolerance.				

Thymosin Alpha-1 10mg		COA: 2603110106	99.699%	PASS
Identity	Thymosin Alpha-1	Lot / Cap Color	White Cap	
Net Content	Not requested	Labeled Amount	10 mg	
Appearance	White Lyophilized Powder	Method	HPLC-UV + LC-MS/MS	
Date Tested	March 11, 2026	Reported	March 12, 2026	
Purity Testing	Purity quantified via HPLC-UV. Sample form: Lyophilized Vial . Tested as reconstitutable lyophilized powder.			
Net content not requested.				

MOTS-C 10mg		COA: 2603110107	99.472%	PASS
Identity	MOTS-C	Lot / Cap Color	Green Cap	
Net Content	12.00 mg	Labeled Amount	10 mg	
Appearance	White Lyophilized Powder	Method	HPLC-UV + LC-MS/MS	
Date Tested	March 11, 2026	Reported	March 12, 2026	
Purity Testing	Purity quantified via HPLC-UV. Sample form: Lyophilized Vial . Tested as reconstitutable lyophilized powder.			
Net content 20% over label.				


DSIP 10mg		COA: 2603110108	99.181%	PASS
Identity	DSIP (Delta Sleep-Inducing Peptide)	Lot / Cap Color	White Cap	
Net Content	Not requested	Labeled Amount	10 mg	
Appearance	White Lyophilized Powder	Method	HPLC-UV + LC-MS/MS	
Date Tested	March 11, 2026	Reported	March 12, 2026	
Purity Testing	Purity quantified via HPLC-UV. Sample form: Lyophilized Vial. Tested as reconstitutable lyophilized powder.			
Net content not requested.				

VCORE PEPTIDES

BPC-157 10mg		COA: 2603110109	99.115%	PASS
Identity	BPC-157	Lot / Cap Color	White Cap	
Net Content	12.58 mg	Labeled Amount	10 mg	
Appearance	White Lyophilized Powder	Method	HPLC-UV + LC-MS/MS	
Date Tested	March 11, 2026	Reported	March 12, 2026	
Purity Testing	Purity quantified via HPLC-UV. Sample form: Lyophilized Vial . Tested as reconstitutable lyophilized powder.			
Lowest purity in dataset; still exceeds 99%.				

VCORE PEPTIDES

Batch Date: March 4, 2026 · Reported: March 5 · 5 samples · Batch Avg 99.725%



Retatrutide 10mg

COA: 2603040073

99.895%

PASS

Identity	GLP RT (Retatrutide)	Lot / Cap Color	Black Cap
Net Content	12.84 mg	Labeled Amount	10 mg
Appearance	White Lyophilized Powder	Method	HPLC-UV + LC-MS/MS
Date Tested	March 4, 2026	Reported	March 5, 2026
Purity Testing	Purity quantified via HPLC-UV. Sample form: Lyophilized Vial . Tested as reconstitutable lyophilized powder.		

Net content 28.4% over label.

Tesamorelin 10mg

COA: 2603040074

99.533%

PASS

Identity	Tesamorelin	Lot / Cap Color	Black Cap
Net Content	12.34 mg	Labeled Amount	10 mg
Appearance	White Lyophilized Powder	Method	HPLC-UV + LC-MS/MS
Date Tested	March 4, 2026	Reported	March 5, 2026
Purity Testing	Purity quantified via HPLC-UV. Sample form: Lyophilized Vial . Tested as reconstitutable lyophilized powder.		

Net content 23.4% over label.

Glow Blend 70mg

COA: 2603040075

99.795%

PASS

Identity	GHK-Cu / BPC-157 / Thymosin Beta-4	Lot / Cap Color	—
Net Content	GHK-Cu 47.77mg · BPC-157 11.05mg · TB4 ~5mg	Labeled Amount	70 mg
Appearance	White Lyophilized Powder	Method	HPLC-UV + LC-MS/MS
Date Tested	March 4, 2026	Reported	March 5, 2026
Purity Testing	Purity quantified via HPLC-UV. Sample form: Lyophilized Vial . Tested as reconstitutable lyophilized powder.		

Tri-peptide blend; all components confirmed.

VCORE PEPTIDES

IPA/CJC-1295 10mg		COA: 2603040076	99.820%	PASS
Identity	Ipamorelin / CJC-1295	Lot / Cap Color	Orange Cap	
Net Content	Ipa 4.02mg · CJC 4.96mg	Labeled Amount	10 mg	
Appearance	White Lyophilized Powder	Method	HPLC-UV + LC-MS/MS	
Date Tested	March 4, 2026	Reported	March 5, 2026	
Purity Testing	Purity quantified via HPLC-UV. Sample form: Lyophilized Vial . Tested as reconstitutable lyophilized powder.			
Dual-peptide blend; total ~9mg.				

Semax 11mg		COA: 2603040077	99.580%	PASS
Identity	Semax	Lot / Cap Color	—	
Net Content	Vial 1: 11.51mg · Vial 2: 11.36mg	Labeled Amount	11 mg	
Appearance	White Lyophilized Powder	Method	HPLC-UV + LC-MS/MS	
Date Tested	March 4, 2026	Reported	March 5, 2026	
Purity Testing	Purity quantified via HPLC-UV. Sample form: Lyophilized Vial . Tested as reconstitutable lyophilized powder.			
Two vials tested; avg purity 99.58%.				

VCORE PEPTIDES

Master Summary — All Samples

#	COA	Product	Identity	Net Content	Purity	Batch
1	2606030687	BPC-157 / TB-500 Blend	BPC-157 / Thymosin Beta-4	BPC-157 11.65mg · TB4 11.33mg	99.270%	June 3
2	2606030688	Retatrutide 10mg	GLP RT (Retatrutide)	12.01 mg	99.940%	June 3
3	2606030689	Tesofensine (Oral)	Tesofensine	Not requested	99.850%	June 3
4	2606030690	BPC-157 (Oral)	BPC-157	Not requested	99.830%	June 3
5	2606030691	SLU-PP-332 (Oral)	SLU-PP-332	Not requested	99.580%	June 3
6	2605070060	Selank 10mg	Selank	13.24 mg	99.970%	May 7
7	2605070061	Epithalon 10mg	Epitalon (Epithalon)	12.62 mg	99.170%	May 7
8	2605070062	KPV 10mg	KPV	12.48 mg	99.490%	May 7
9	2605070063	Sermorelin 10mg	Sermorelin	10.56 mg	99.100%	May 7
10	2605070065	IGF-1 LR3	IGF-LR3	0.88 mg	99.700%	May 7
11	2605070066	GHK-Cu 100mg	GHK-Cu	102.93 mg	99.060%	May 7
12	2604030139	Retatrutide 20mg	GLP RT (Retatrutide)	24.55 mg	99.924%	April 3
13	2604030141	Retatrutide 10mg	GLP RT (Retatrutide)	12.81 mg	99.889%	April 3
14	2604030142	Epithalon 50mg	Epitalon (Epithalon)	46.71 mg	99.484%	April 3
15	2604030143	PT-141 10mg	PT-141 (Bremelanotide)	9.71 mg	99.821%	April 3
16	2604030144	SS-31 10mg	SS-31 (Elamipretide)	9.55 mg	99.759%	April 3
17	2604030145	Glutathione 1500mg	Glutathione	1481.26 mg	99.541%	April 3
18	2604030146	Unknown / Unlabeled	Melanotan-II (by LC-MS/MS)	9.61 mg	99.667%	April 3
19	2603240023	Retatrutide 10mg	GLP RT (Retatrutide)	12.21 mg	99.791%	March 24
20	2603240024	Tirzepatide 50mg	GLP TZ (Tirzepatide)	58.01 mg	99.569%	March 24
21	2603240025	BPC-157 / TB-500 Blend	BPC-157 / Thymosin Beta-4	BPC-157 11.88mg · TB4 10.94mg	99.002%	March 24
22	2603240026	AOD-9604 10mg	AOD-9604	13.62 mg	99.749%	March 24
23	2603240027	Glow Blend 70mg	GHK-Cu / BPC-157 / Thymosin Beta-4	GHK-Cu 48.38mg · BPC-157 10.31mg · TB4 ~5mg	99.521%	March 24
24	2603240028	5-Amino 1MQ	5-Amino 1MQ	6.41 mg	99.029%	March 24
25	2603110102	PT-141 10mg	PT-141 (Bremelanotide)	9.93 mg	99.959%	March 11
26	2603110103	Tirzepatide	GLP TZ (Tirzepatide)	Not requested	99.891%	March 11
27	2603110104	TB-500 5mg	Thymosin Beta-4	5.77 mg	99.498%	March 11
28	2603110105	NAD+ 500mg	NAD+	459.27 mg	99.822%	March 11
29	2603110106	Thymosin Alpha-1 10mg	Thymosin Alpha-1	Not requested	99.699%	March 11
30	2603110107	MOTS-C 10mg	MOTS-C	12.00 mg	99.472%	March 11
31	2603110108	DSIP 10mg	DSIP (Delta Sleep-Inducing Peptide)	Not requested	99.181%	March 11
32	2603110109	BPC-157 10mg	BPC-157	12.58 mg	99.115%	March 11
33	2603040073	Retatrutide 10mg	GLP RT (Retatrutide)	12.84 mg	99.895%	March 4
34	2603040074	Tesamorelin 10mg	Tesamorelin	12.34 mg	99.533%	March 4
35	2603040075	Glow Blend 70mg	GHK-Cu / BPC-157 / Thymosin Beta-4	GHK-Cu 47.77mg · BPC-157 11.05mg · TB4 ~5mg	99.795%	March 4
36	2603040076	IPA/CJC-1295 10mg	Ipamorelin / CJC-1295	Ipa 4.02mg · CJC 4.96mg	99.820%	March 4

VCORE PEPTIDES

#	COA	Product	Identity	Net Content	Purity	Batch
37	2603040077	Semax 11mg	Semax	Vial 1: 11.51mg · Vial 2: 11.36mg	99.580%	March 4